<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Cadex Genomics on Medium]]></title>
        <description><![CDATA[Stories by Cadex Genomics on Medium]]></description>
        <link>https://medium.com/@cadexgenomics?source=rss-9ca00480cfe0------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*Qt6lVonlQ7-TF0xaM60vJw.jpeg</url>
            <title>Stories by Cadex Genomics on Medium</title>
            <link>https://medium.com/@cadexgenomics?source=rss-9ca00480cfe0------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 16:08:47 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@cadexgenomics/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Molecular Diagnostics: A Broken Business Model or Flawed Execution?]]></title>
            <link>https://medium.com/@cadexgenomics/molecular-diagnostics-a-broken-business-model-or-flawed-execution-2fa9407bd867?source=rss-9ca00480cfe0------2</link>
            <guid isPermaLink="false">https://medium.com/p/2fa9407bd867</guid>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[commercialization]]></category>
            <category><![CDATA[therapy]]></category>
            <category><![CDATA[therapeutics]]></category>
            <category><![CDATA[diagnostic]]></category>
            <dc:creator><![CDATA[Cadex Genomics]]></dc:creator>
            <pubDate>Thu, 16 Apr 2020 00:19:32 GMT</pubDate>
            <atom:updated>2020-04-16T03:24:39.290Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5CBx1Wpg_-KGTp8da1vZbw.jpeg" /></figure><p>It is common to hear concerns from investors and other stakeholders about the business case for molecular diagnostics. One life science investor recently sent the following message to us: “Even though we feel diagnostic (Dx) approaches are desperately needed and provide a huge benefit to patients and society, having made a couple of Dx investments, we know the business case to be more difficult.” This article is an attempt to put some perspective on the perceived business case challenges for molecular diagnostic tests and to help molecular diagnostic companies improve the odds of commercial success for their new tests. The article also offers investors a perspective to evaluate molecular diagnostic investments.</p><p>The perception that the business case for molecular diagnostics is more difficult than for therapeutics is primarily due to molecular diagnostics generally being adopted by physicians more slowly and reimbursement taking longer when compared with therapeutics. The main driver behind this slower adoption and reimbursement for molecular diagnostics is the different regulatory pathways available for these two product categories. These appropriately differing pathways exist because the risk profile for diagnostic tests is significantly lower than for pharmaceuticals.</p><p>Before a drug may be marketed, it must first be approved by the FDA. To win FDA approval, the drug manufacturer must submit an application that includes data demonstrating to FDA scientists that the drug is both safe and efficacious. Once the FDA is satisfied with the application, a premarket approval (PMA) is issued, allowing the manufacturer to market the drug to physicians. Based on the FDA’s PMA, physicians and payors naturally assume the drug is both safe and efficacious (e.g. has clinical utility).</p><p><strong>“Even though we feel Dx approaches are desperately needed and provide a huge benefit to patients and society, having made a couple of Dx investments, we know the business case to be more difficult.”</strong></p><p>Conversely, most diagnostic tests are commercialized as laboratory-developed tests (LDTs). LDTs are tests performed at a single lab location and regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). A CLIA certificate is provided to a lab once it demonstrates that a lab test is <em>analytically</em> valid, meaning that the test’s analytical process is accurate and reproducible. Under CLIA, there is no requirement for the test developer to provide evidence demonstrating that the test delivers clinical value (also known as clinical utility) to a patient. As a result, the sufficiency of clinical utility evidence for these tests is determined by physicians, payors, professional societies, and health technology assessment (HTA) groups. So, even though an LDT may be commercialized without clinical utility evidence, providing evidence of clinical utility is <em>critical</em> for that test to achieve commercial success.</p><p>To illustrate this, let’s imagine a lab discovers a marker named Marker X that is present in the blood of some cancer patients. After some hard work, this lab demonstrates to CLIA that the lab is able to measure the presence of Marker X with great precision and reproducibility. With these findings alone, this lab can offer the Marker X test to physicians under a CLIA certificate. But what’s missing? The lab has not demonstrated that detecting Marker X in the blood leads to improved clinical decision making. That is, the lab has not provided any evidence of clinical utility for Marker X.</p><p>For a test to have clinical utility it must provide information to the physician that is both clinically relevant, valid, and clinically actionable so that use of the test leads to improved health outcomes. Clinical <em>validity</em> refers to the ability of a test to detect the presence of disease or to predict the likelihood that medical intervention will be effective. For a test to demonstrate clinical <em>utility</em>, the test must be clinically valid <em>and</em> there must be strong evidence that physicians use the information provided by the test to change the way they treat their patients and that the new or modified treatment informed by the test leads to improved patient outcomes. For example, a test that can successfully identify a pathogenic germline mutation for which there is no medical intervention available may be clinically valid but is highly unlikely to have any clinical utility.</p><p>Until a test has been shown to provide clinical utility, physicians will not broadly adopt the test and insurance carriers will certainly not pay for the test. A key question to ask is: How do physicians and those responsible for reimbursement decisions know when a lab has adequately demonstrated clinical utility for a test? Understanding the dynamics around the answers to this question is the key to understanding the adoption process for molecular diagnostics versus drugs. We explore these dynamics in the paragraphs that follow.</p><p>One key to understanding the slower adoption of LDTs versus drugs is that many of these tests are commercially marketed <em>before</em> the clinical studies are started and completed that would demonstrate clinical utility. The adoption clock for tests starts when commercialization begins so the adoption cycle typically takes longer for LDTs post commercialization since, for many tests, the evidence required for adoption is developed post-marketing. This is illustrated in Figure 1 below.</p><p><strong>Figure 1: Timing of Clinical Evidence Development: LDT versus Drug</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*i8DPgVM0dX413DrujIejlw.png" /></figure><p>If more clinical studies for LDTs were completed prior to commercial launch the adoption cycle would look more similar to that for pharmaceuticals.</p><p><strong>“If the clinical endpoints and the powering of the clinical study are sufficient to demonstrate improved patient outcomes, the LDT is likely to achieve broad reimbursement coverage and is also likely to achieve broad clinical adoption by physicians.”</strong></p><p>Another important dynamic for LDTs is once the clinical utility studies have been successfully completed, the data must be published in peer-reviewed medical journals for review by key opinion leaders (KOLs), professional societies, health technology assessment groups, and third-party payors in order for them to assess the utility of a novel LDT. This process may be as slow as the FDA PMA review and can also contribute to the slower adoption of novel LDTs post commercialization when compared to drugs.</p><p>Finally, we all know that many clinical studies fail. When this happens in a drug study, the drug is said to have failed in clinical development. We do not call it a commercial failure. However, for LDTs, because the clinical utility studies are often conducted post-marketing, those clinical failures are frequently considered <em>commercial failures</em> because the test fails to gain market adoption and payors refuse to reimburse the lab for the test. Failures for LDTs that are classified as <em>commercial failures</em> are actually <em>clinical development</em> failures.</p><p>To maximize the probability of commercial success for an LDT, companies need to consider the following:</p><p>1. Is there a well-defined intended use for the test? A well-defined intended use should answer these two basic questions:</p><p>a. What patient population is the test intended for? Example: All patients suspected of having COPD and that have had an indeterminate spirometry test result.</p><p>b. What clinical question is the test attempting to answer? Example: Identify, within 12 to 21 days, patients whose stage IV cancer is progressing.</p><p>2. Is there a well-defined clinical development plan supportive of the intended use that is sufficient for achieving broad adoption and reimbursement? Here is a rule of thumb for answering that question: If the endpoints and the powering of a clinical study are sufficient to demonstrate improved patient outcomes, the LDT is likely to achieve broad reimbursement coverage and it is also likely to achieve broad clinical adoption by physicians.</p><p>3. Is the company’s management fully committed to completing its clinical development plan? If the answer is no, then stop. Failure is all but guaranteed.</p><p>4. Is the timing of commercial launch and commercial investment appropriately linked to the publication of the clinical utility studies? Developers of LDTs should time commercial launch after sufficient evidence has been developed to justify making the test available to patients. First, a patient’s health can be negatively impacted if a test leads to an unsound clinical decision. From a business perspective, without adequate published evidence of clinical utility, a test will not be reimbursed, and commercial adoption will be difficult.</p><p>5. Is a plan in place for driving acceptance of the evidence from key stakeholders: HTAs, KOLs, payors, professional societies, etc.? What is the publication plan for the clinical utility data? What is the plan for KOL development? What is the reimbursement strategy? What is the plan for ensuring that HTAs and professional societies are aware of the LDT and actively assessing the test? These are all important questions for pharmaceutical companies launching a new drug, but they are even more important for LDT service providers as it will determine physician adoption and reimbursement.</p><p>A well-defined strategic plan and strong execution do not eliminate the challenges of developing and commercializing a novel LDT. However, they can greatly accelerate the rate of commercial adoption and reimbursement and can also greatly improve the probability of commercial success. As with all life-science categories, the molecular diagnostics business has its share of challenges, but the business model for molecular diagnostics is far from broken.</p><p><em>Bill Haack and Greg Schafer are co-founders of Cadex Genomics. Bill is the CEO and Greg is the CCO. Cadex Genomics is developing a blood-based real-time therapy monitoring LDT for patients with stage IV solid tumors.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2fa9407bd867" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Case for Real-Time Cancer Therapy Monitoring]]></title>
            <link>https://medium.com/@cadexgenomics/the-case-for-real-time-cancer-therapy-monitoring-9249b1ec3bd6?source=rss-9ca00480cfe0------2</link>
            <guid isPermaLink="false">https://medium.com/p/9249b1ec3bd6</guid>
            <category><![CDATA[therapy]]></category>
            <category><![CDATA[liquid-biopsy]]></category>
            <category><![CDATA[lung-cancer]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[colon-cancer]]></category>
            <dc:creator><![CDATA[Cadex Genomics]]></dc:creator>
            <pubDate>Fri, 10 May 2019 17:28:09 GMT</pubDate>
            <atom:updated>2019-05-12T19:14:28.884Z</atom:updated>
            <cc:license>http://creativecommons.org/publicdomain/zero/1.0/</cc:license>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*BMbYIr6XbHYgWQDtqvR-jw.jpeg" /></figure><p>Tragically, most patients with metastatic cancer (a stage IV cancer diagnosis) ultimately die from their disease. For these late-stage cancer patients, the goal of treatment is to extend survival while maintaining or improving the quality of life for the patient.</p><p>Physicians have to make difficult decisions by balancing the perceived benefits of drug therapy versus the toxicity and side effects impacting the quality of life for the patient.</p><p>Cancer drugs are designed to attack, destroy and shrink cancer cells and come with a spectrum of side-effects which often are toxic and lead to a reduced quality of life for patients. Many of the newest and most beneficial cancer drugs are also <a href="https://www.biospace.com/article/why-does-immunotherapy-cost-so-much-/">very expensive</a>. With some cancer drugs, a single dose can cost more than $20,000 USD.</p><p>Unfortunately, many patients are exposed to toxic therapy with no improvement in survival. While cancer diagnostic tests from companies like <a href="https://www.foundationmedicine.com/genomic-testing">Foundation Medicine</a>, <a href="https://guardanthealth.com/">Guardant</a> and others enable physicians to target treatment for specific types of cancer tumors and mutations, there is limited precision regarding which cancer patients will actually benefit from a targeted therapy versus those who will not benefit.</p><p>Scientists, researchers, and clinicians are continually working to improve their understanding of the complexity of cancer biology. Cancer drug companies and diagnostic companies strive to personalize cancer therapy for the patient as well as targeting specific tumors or tumor mutations, but, until researchers and physicians know with a high degree of certainty which cancer patient will respond to a specific therapy, some patients will receive none of the life-extending survival benefits of therapy but all of the toxicity and side effects associated with treatment .</p><p>The concept of real-time cancer therapy monitoring is to rapidly identify patients who are not responding to cancer drug therapy. The current standard of care for monitoring cancer therapy non-response (or response) uses radiologic imaging techniques to measure a cancer patient’s tumor growth or shrinkage at regular intervals, usually every 8 to 12 weeks. If the imaging results indicate the patient’s tumor is growing, the physician and patient know that the drug therapy is not working. Current tumor imaging techniques often lack precision, can be expensive, time-consuming and expose the patient to radiation. Imaging usually requires weeks or months, after the initiation of therapy, for tumor response to be visible. If a tumor is not responding to therapy, patients wait weeks or months to switch to a treatment that may provide benefits.</p><p>An opportunity exists to determine if a patient with late-stage cancer is responding to therapy as soon as possible after the first dose is given instead of waiting weeks or months for assessment via radiologic imaging. The perfect scenario would be to know if a cancer therapy would work before treating a patient. Another scenario would be to know if a drug therapy is working as soon as possible after treatment starts. A quick assessment of therapy effectiveness would avoid continuing a therapy that is not working and enable the patient and physician to make earlier decisions about drug treatment options that may be more effective.</p><p>The benefits of real-time cancer therapy monitoring are:</p><p>- patients have limited exposure to the toxicities of a drug therapy that is not working; and</p><p>- patients can quickly move to a different drug therapy that may work; and,</p><p>- the patient and the healthcare ecosystem do not incur the ongoing cost of a cancer drug that is not providing any life-extending benefit.</p><p>There are a number of diagnostics companies working on real-time cancer therapy monitoring tests. Most of the real-time cancer therapy monitoring diagnostic tests work by measuring the <a href="https://en.wikipedia.org/wiki/Cell-free_fetal_DNA">cell-free DNA (cfDNA)</a> fragments found circulating in the blood. The release of cfDNA into the <a href="https://en.wikipedia.org/wiki/Bloodstream">bloodstream</a> is driven by the primary <a href="https://en.wikipedia.org/wiki/Neoplasm">tumor</a>, <a href="https://en.wikipedia.org/wiki/Tumor_cell">tumor cells</a> that circulate in <a href="https://en.wikipedia.org/wiki/Peripheral_blood">peripheral blood</a>, metastatic deposits and normal cell types. Tumor cells and cfDNA circulate in the bloodstream of all patients with cancer.</p><p><a href="https://www.cadexgenomics.com/#">Cadex Genomics</a> has developed a diagnostic test (we call the test Alibrex) that can measure the quantity of cfDNA in a patient’s blood before cancer drug therapy starts and then two-weeks later to determine if a patient’s cancer tumor is progressing (i.e. tumor size is increasing) — indicating that the drug therapy is not working. We are currently conducting an IRB-approved clinical study at various cancer treatment centers to validate that Alibrex delivers actionable clinical results. Read more about the clinical study <a href="https://www.cadexgenomics.com/news/6b6ceef9-16b9-4278-985d-ed250b09780c">here</a>.</p><p><a href="https://www.cadexgenomics.com/team">Bill Haack</a> is the founder and CEO of Cadex Genomics.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9249b1ec3bd6" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>